Cellular Biomedicine Opens Beijing Facility

Cellular Biomedicine, a China-US cell therapy company, officially opened a GMP manufacturing facility in the PKUCare Industrial Park of Beijing. CBMG is developing stem cell products for joint and autoimmune disorders, and earlier this year, the company in-licensed CAR-T immuno-oncology technology from the Chinese PLA General Hospital (the 301 hospital) of Beijing. CBMG is headquartered in Cupertino, California, but China is its primary market. The new facility in Beijing adds capacity to CBMG's existing plants in WuXi and Shanghai. More details.... Stock Symbol: (NSDQ: CBMG) Share this with colleagues: // //